Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
ACTIVE_NOT_RECRUITING
Status
Conditions
- Adrenal Cortical Carcinoma
- Alveolar Soft Part Sarcoma
- Central Nervous System Neoplasm
- Childhood Clear Cell Sarcoma of Soft Tissue
- Clear Cell Sarcoma of Soft Tissue
- Ewing Sarcoma
- Hepatoblastoma
- Hepatocellular Carcinoma
- Osteosarcoma
- Recurrent Adrenal Cortical Carcinoma
- Recurrent Alveolar Soft Part Sarcoma
- Recurrent Clear Cell Sarcoma of Soft Tissue
- Recurrent Ewing Sarcoma
- Recurrent Hepatoblastoma
- Recurrent Hepatocellular Carcinoma
- Recurrent Kidney Wilms Tumor
- Recurrent Malignant Solid Neoplasm
- Recurrent Osteosarcoma
- Recurrent Primary Malignant Central Nervous System Neoplasm
- Recurrent Renal Cell Carcinoma
- Recurrent Rhabdomyosarcoma
- Recurrent Soft Tissue Sarcoma
- Recurrent Thyroid Gland Medullary Carcinoma
- Refractory Adrenal Cortical Carcinoma
- Refractory Alveolar Soft Part Sarcoma
- Refractory Clear Cell Sarcoma of Soft Tissue
- Refractory Ewing Sarcoma
- Refractory Hepatoblastoma
- Refractory Hepatocellular Carcinoma
- Refractory Malignant Solid Neoplasm
- Refractory Osteosarcoma
- Refractory Primary Central Nervous System Neoplasm
- Refractory Primary Malignant Central Nervous System Neoplasm
- Refractory Renal Cell Carcinoma
- Refractory Rhabdomyosarcoma
- Refractory Soft Tissue Sarcoma
- Refractory Thyroid Gland Medullary Carcinoma
- Refractory Wilms Tumor
- Renal Cell Carcinoma
- Rhabdomyosarcoma
- Soft Tissue Sarcoma
- Solid Neoplasm
- Thyroid Gland Medullary Carcinoma
- Wilms Tumor
Interventions
- DRUG: Cabozantinib
- DRUG: Cabozantinib S-malate
- OTHER: Pharmacological Study
Sponsor
National Cancer Institute (NCI)